Allarity Therapeutics Receives U.S. Patent Covering Stenoparib Treatment Regimens Into 2045
The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity's clinical development program. They also encompass methods of
